Strides invests in 'promising' Oncobiologics
This article was originally published in Scrip
Executive Summary
Strides Arcolab of India has invested in the privately held US firm, Oncobiologics, known to be developing a clutch of biosimilars, including versions of Humira (adalimumab), Herceptin (trastuzumab) and Rituxan (rituximab) in addition to other novel biotherapeutics.